[A22-48] Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2022
Project no.:
A22-48
Commission:
Commission awarded on 15.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults and adolescents from 12 years of age and weighing at least 40 kilograms with COVID-19 who do not require supplemental oxygen and who are at increased risk of their disease becoming severe
- Patients ≥ 18 years: hint of a considerable added benefit
- Patients ≥ 12 to < 18 years: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-47 | Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V | Commission completed |